What if a cell therapy could work with the immune system rather than against it?
iPS cell therapies have enormous potential to cure cancer and many devastating diseases, but they’re hindered by the patient’s immune response.
This is Shinobi, the first iPS cell therapy compatible with the patient’s immune system.
Shinobi’s comprehensive immune evasion technology not only shields against T-cells and innate immunity, but also against antibody-mediated rejection.
Shinobi’s immune evasive iPS-T cell therapy revolutionizes cancer treatment by offering:
Increased persistence
Reduced lymphodepletion
Redosability
Off-the-shelf availability
We’re starting with CD8ɑβ iPS-T cell therapies to target solid tumor cancers.
Solid tumors constitute the majority of adult cancers and remain the most difficult to cure.
Fully armored, immune evasive CD8ɑβ iPS-T cells with plug-and-play antigen specificity
Our Katana platform enables a master cell bank of untargeted iPS-T cells that is amenable to rapid pipeline expansion by introduction of CARs or TCRs.
Better outcomes for more patients
Significantly faster
pipeline build
Substantially cheaper
than today’s therapies
Durable patient responses through re-dosing
“Shinobi's Katana platform has the potential to make CAR-T cell therapies accessible to patients on a global scale.”
Carl June, M.D.
Pioneer of CAR-T cell therapy and member of Shinobi’s Scientific Advisory Board
With roots in Kyoto and South San Francisco, we’re led by an unrivaled team of industry leaders and pioneers.
Daniel Kemp, Ph.D.
CEO
Successful builder of multiple cell therapy companies including allogeneic T-cell, NK cell and γ𝛅T cell platforms
Shin Kaneko, M.D., Ph.D.
Co-Founder
Pioneer of iPS-T cell research and Deputy Director at Center of iPS Cell Research and Application (CiRA) at Kyoto University
Tobias Deuse, M.D.
Co-Founder
World-renowned leader in immune evasion technology and transplant surgeon at UCSF
By evading the immune system, we are...
making cell therapies accessible
…by slashing costs, cutting timelines, and providing treatments for millions of patients.
treating solid tumors
…by addressing tumor heterogeneity and enabling redosing for greater efficacy.
going beyond cancer
…and treating a wide range of intractable diseases, including autoimmune disorders.
What others are saying about Shinobi:
“The concept of the immune checkpoint engager opened a new era of using synthetic molecules in hypoimmune engineering... especially for CAR-T and iPSC-derived cells.”
Cell Stem Cell / Preview Nov ‘23
Highlight for Shinobi publication on novel SIRPa engager technologyShinobi Publications
Our technology has been validated in numerous publications. Most recently…
Pipeline
Sharing its name with the Japanese term for ‘ninja’, Shinobi has aptly named its pipeline ‘NJA’.
NJA-001 (CD8⍺β T cell)
GPC3+ HLA-A24 solid tumors
Discovery
Preclinical
Clinical
Preclinical
NJA-002 (CD8⍺β T cell)
Undisclosed TCR for solid tumors
Discovery
Preclinical
Clinical
Preclinical
NJA-003 (CD8⍺β T cell)
GPC3+ HLA-A2 solid tumors
Discovery
Preclinical
Clinical
Discovery
NJA-004 (CD8⍺β T cell)
Undisclosed CAR for autoimmune diseases
Discovery
Preclinical
Clinical
Preclinical
NJA-005 (Pancreatic beta cell)
Type 1 Diabetes
Discovery
Preclinical
Clinical
Discovery
Partnerships
Shinobi partners with top-tier institutions to consistently source and advance groundbreaking research in immune evasive iPSC-derived cell therapies.
